CN106974992A - 一种增加骨密度的组合物及其应用 - Google Patents
一种增加骨密度的组合物及其应用 Download PDFInfo
- Publication number
- CN106974992A CN106974992A CN201710233326.2A CN201710233326A CN106974992A CN 106974992 A CN106974992 A CN 106974992A CN 201710233326 A CN201710233326 A CN 201710233326A CN 106974992 A CN106974992 A CN 106974992A
- Authority
- CN
- China
- Prior art keywords
- weight
- parts
- concentrate
- safflower
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000037182 bone density Effects 0.000 title claims abstract description 28
- 239000000203 mixture Substances 0.000 title claims abstract description 26
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 18
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract description 18
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 12
- 244000144730 Amygdalus persica Species 0.000 claims abstract description 9
- 235000003717 Boswellia sacra Nutrition 0.000 claims abstract description 9
- 240000007551 Boswellia serrata Species 0.000 claims abstract description 9
- 235000012035 Boswellia serrata Nutrition 0.000 claims abstract description 9
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims abstract description 9
- 244000241257 Cucumis melo Species 0.000 claims abstract description 9
- 235000009847 Cucumis melo var cantalupensis Nutrition 0.000 claims abstract description 9
- 240000008067 Cucumis sativus Species 0.000 claims abstract description 9
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 claims abstract description 9
- 241001148782 Davallia Species 0.000 claims abstract description 9
- 241000123589 Dipsacus Species 0.000 claims abstract description 9
- 239000004863 Frankincense Substances 0.000 claims abstract description 9
- 235000006040 Prunus persica var persica Nutrition 0.000 claims abstract description 9
- 240000004824 Trimezia steyermarkii Species 0.000 claims abstract description 9
- 229910052802 copper Inorganic materials 0.000 claims abstract description 9
- 239000010949 copper Substances 0.000 claims abstract description 9
- 239000009136 dragon's blood Substances 0.000 claims abstract description 9
- 239000002689 soil Substances 0.000 claims abstract description 9
- 240000007311 Commiphora myrrha Species 0.000 claims abstract description 8
- 235000006965 Commiphora myrrha Nutrition 0.000 claims abstract description 8
- 241000112528 Ligusticum striatum Species 0.000 claims abstract description 8
- 235000007265 Myrrhis odorata Nutrition 0.000 claims abstract description 8
- 244000144725 Amygdalus communis Species 0.000 claims abstract description 7
- 235000011437 Amygdalus communis Nutrition 0.000 claims abstract description 7
- 235000020224 almond Nutrition 0.000 claims abstract description 7
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 6
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 6
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000002253 acid Substances 0.000 claims abstract description 6
- 235000008434 ginseng Nutrition 0.000 claims abstract description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 6
- 229960003080 taurine Drugs 0.000 claims abstract description 6
- 229920001661 Chitosan Polymers 0.000 claims abstract description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 5
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 claims abstract 4
- 239000003814 drug Substances 0.000 claims description 49
- 229940079593 drug Drugs 0.000 claims description 39
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 24
- 239000000284 extract Substances 0.000 claims description 23
- 239000012141 concentrate Substances 0.000 claims description 20
- 239000008213 purified water Substances 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 230000000694 effects Effects 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 8
- 230000008859 change Effects 0.000 claims description 5
- 235000013402 health food Nutrition 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- AZHSSKPUVBVXLK-UHFFFAOYSA-N ethane-1,1-diol Chemical compound CC(O)O AZHSSKPUVBVXLK-UHFFFAOYSA-N 0.000 claims description 4
- 235000013305 food Nutrition 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 239000013049 sediment Substances 0.000 claims description 3
- -1 aminohexose Substances 0.000 claims description 2
- 241000208340 Araliaceae Species 0.000 claims 4
- 244000241872 Lycium chinense Species 0.000 claims 4
- 235000015468 Lycium chinense Nutrition 0.000 claims 4
- 239000000706 filtrate Substances 0.000 claims 3
- 238000001914 filtration Methods 0.000 claims 3
- 244000018633 Prunus armeniaca Species 0.000 claims 2
- 235000009827 Prunus armeniaca Nutrition 0.000 claims 2
- 238000001556 precipitation Methods 0.000 claims 2
- 241000219094 Vitaceae Species 0.000 claims 1
- 230000006837 decompression Effects 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 235000021021 grapes Nutrition 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 abstract description 25
- 244000131316 Panax pseudoginseng Species 0.000 abstract description 2
- 230000005856 abnormality Effects 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 230000037396 body weight Effects 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 210000002303 tibia Anatomy 0.000 description 7
- 208000010392 Bone Fractures Diseases 0.000 description 6
- 210000001672 ovary Anatomy 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 241000700159 Rattus Species 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 230000032683 aging Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 210000000689 upper leg Anatomy 0.000 description 3
- 102000055006 Calcitonin Human genes 0.000 description 2
- 108060001064 Calcitonin Chemical class 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 244000170916 Paeonia officinalis Species 0.000 description 2
- 235000006484 Paeonia officinalis Nutrition 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 229960004015 calcitonin Drugs 0.000 description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical class N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 108010048734 sclerotin Proteins 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 240000008384 Capsicum annuum var. annuum Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010061619 Deformity Diseases 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical class [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 208000030136 Marchiafava-Bignami Disease Diseases 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- 206010039984 Senile osteoporosis Diseases 0.000 description 1
- 206010061363 Skeletal injury Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000037118 bone strength Effects 0.000 description 1
- 230000008416 bone turnover Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940091249 fluoride supplement Drugs 0.000 description 1
- 150000002222 fluorine compounds Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 230000008338 local blood flow Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 235000015091 medicinal tea Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 210000004409 osteocyte Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
- A61K36/12—Filicopsida or Pteridopsida
- A61K36/126—Drynaria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/758—Zanthoxylum, e.g. pricklyash
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Insects & Arthropods (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种增加骨密度的组合物及其应用,成分包括D-葡萄糖醛酸、氨基己糖、壳寡糖、壳聚糖、牛磺酸氨基单糖、人参、黄瓜子、制乳香、制没药、当归、藏红花、红花、血竭、桃仁、甜瓜子、土元、骨碎补、川牛膝30重量份、川断、川椒、川芎、自然铜、赤芍、杏仁,该组合物能解决骨密度异常的问题,能从根本上对骨质疏松症进行防治。
Description
技术领域
本发明涉及组合物技术领域,以及组合物在制备药物和保健食品中的应用。
背景技术
随着人年龄的增长,人体的微循环会越来越差,很多老年人冬天腿脚会很凉,也就是人们常说的:人老脚先老。这说明身体的循环变弱,局部血流量减少,血液中的营养物质不能及时充分供应组织。特别是由于骨血流量的减少,骨骼所需要的各种营养不能及时得到补充,造成骨营养缺乏。老年人由于内分泌的改变,骨矿物质大量流失,长时间骨营养不良,骨质形成(成骨细胞)作用减少,骨吸收(破骨细胞)作用增强,形成骨质疏松。
骨质疏松症是一种复杂的、由多种因素产生的慢性病变过程,是中老年人的常见疾病、多发病,主要临床表现为腰背痛、畸形、骨折、呼吸系统障碍等,其中骨折为骨质疏松症最常见和严重的并发症之一,极大的影响人们的生活质量。
骨质疏松症发病率高,危害性大,已受到全球医学界的高度重视,世界卫生组织将其列为三大老年病之一。目前全世界约2亿人患有骨质疏松,其发病率已跃居常见病、多发病的第7位。随着人口老龄化日趋明显,尤其是我国在未来人口老龄化会更加严重,老年型社会逐步形成的状况下,作为中老年多发的退行性疾病—骨质疏松症及其并发症,已成为一个社会性的健康问题而备受老年病学者的关注,并引起了各国政府的高度重视,因此将每年10月20日定为“国际骨质疏松日”。
骨质疏松症是一个复杂性疾病,往往是许多因素综合作用的结果。防治骨质疏松症是一个十分复杂的问题,一旦出现骨质疏松再纠正就极为困难。现代医学认为,骨质疏松症是一种全身性的代谢性骨病,以骨量减少、骨的微结构破坏为特征,导致骨的脆性增加,容易发生骨折。防治骨质疏松症的最终目的是减少骨折的发生,提高中老年人的生活质量,我们可以通过延缓和减少骨量丢失,争取重获骨量,增加骨骼强度来达到此目的。其基本措施包括摄入充足的钙、适当的体力活动以及预防骨损伤,并在此基础上予以不同的药物干预,最终达到预防及治疗骨折的目的。对于骨质疏松症,目前,临床治疗该病使用最多的是雌激素、钙剂、活性维生素D、降钙素和氟化物等药物,虽然取得了一定疗效,但西医学治疗的毒性不良反应是普遍存在的,比如长期用合成的雌激素类药物会导致乳腺和子宫内膜的异常增生,双磷酸盐类的次序使用会降低骨转换率、增加骨脆性,氟化物类单用时会导致骨软化,维生素D类和降钙素存在变态反应。
相对于西医在治疗中存在的不足,中医药在防治老年骨质疏松症方面有独特的优势,同时也避免了激素替代等西医治疗的严重副反应,近年来在临床试验研究方面作了大量工作,有了较大的进步。在中医学中骨质疏松症属于“骨萎”、“骨痹”范畴。中医学认为,骨质疏松症与肾虚、脾虚、血瘀有着密切的关系,其中肾虚是本病的主要病因,“多虚多瘀”是骨质疏松症的病理特点。因此,骨质疏松在预防和治疗中应以肾为根本,以脾胃为基础,辨证论治,通过益肾壮骨、补齐健脾、化瘀,达到预防骨质疏松的目的。为此,本发明根据中医对骨的认识及现代药理学,提供一种具有增加骨密度作用的药物组合物。
发明内容
为此,本发明所要解决的技术问题在于提供一种具有增加骨密度作用的组合物及其制备方法。
为解决上述技术问题,本发明提供了一种具有增加骨密度作用的组合物,其原料重量组成为:黄瓜子10—80重量份、制乳香2—50重量份、制没药2—50重量份、当归3—60重量份、藏红花2—30重量份、红花5—50重量份、血竭5—50重量份、桃仁3—50重量份、甜瓜子10—60重量份、土元5—50重量份、骨碎补5—50重量份、川牛膝3--50重量份、川断5—50重量份、川椒5—50重量份、川芎5—50重量份、自然铜2—20重量份、赤芍5—50重量份、杏仁3--50重量份。
优选的,所述组合物的原料重量组成为:黄瓜子50重量份、制乳香30重量份、制没药30重量份、当归30重量份、藏红花20重量份、红花30重量份、血竭30重量份、桃仁30重量份、甜瓜子30重量份、土元30重量份、骨碎补30重量份、川牛膝30重量份、川断30重量份、川椒30重量份、川芎30重量份、自然铜10重量份、赤芍30重量份、杏仁40重量份。
本发明提供了一种组合物的制备方法,包括如下步骤:
(1)按照选定重量份数称取当归、藏红花、红花,加入10倍药物重量的质量浓度为75%乙醇提取2次,每次1.5h,合并提取液并过滤,回收乙醇并减压浓缩至60℃下相对密度1.20的浓缩液I,备用;
(2)按照选定重量份数称取血竭、桃仁、甜瓜子、土元、骨碎补、川牛膝,加入纯化提取2次,第一次加10倍药物重量的纯化水提取2h,第二次加10倍药物重量的纯化水提取1h,合并提取液并过滤,浓缩至80℃下相对密度1.15的浓缩液II,备用;
(3)按照选定重量份数称取黄瓜子、制乳香、制没药、川断、川椒、川芎、自然铜、赤芍、杏仁,加入纯化水提取2次,第一次加10倍药物重量的纯化水提取2h,第二次加10倍药物重量的纯化水提取1h,过滤、减压浓缩至60℃下相对密度1.20的浓缩液,并加入70%乙醇醇沉,取上清液回收乙醇,将所得沉淀物减压浓缩至60℃下相对密度1.15的浓缩液III,备用;
(4)合并上述浓缩液I、II和III,干燥,得浸膏粉,然后按照常规工艺制成临床上可接受的剂型。
上述药物组合物添加常规辅料,按照常规工艺制成临床上可接受的胶囊剂、片剂、颗粒剂、合剂、煎膏剂、丸剂、冲剂、滴丸、茶剂、酊剂、酒剂、饮料、糖果或烘焙食品
本发明提供了一种由上述的药物组合物添加常规辅料,按照常规工艺制备得到的药物制剂、保健食品或食品。
本发明提供了上述的药物组合物在制备具有增加骨密度作用的药物或保健食品用途以及制备防治骨质疏松症的药物、保健食品或食品中的用途。
本发明的有益效果如下:
通过改变骨微循环,疏通气血,增加骨血流量,同时给骨骼提供充足的营养,促进代谢,提高骨营养状况,改善骨质,排除骨垃圾,修复受损衰老的骨细胞,达到壮骨、健骨、强骨增加骨密度的目的。由于骨骼中血流量的增加,骨骼所需要的各种营养物质得到了充分的补充,骨营养增加后骨质得以改善。
附图说明
图1第一组正常对照组的小鼠胫骨骨密度变化图。
图2第二组摘除两侧卵巢组的小鼠胫骨骨密度变化图。
图3第三组摘除两侧卵巢并用药组的小鼠胫骨骨密度变化图。
具体实施方式
1制备组合物
本发明实验的需要,按照下表数据进行了5组实验:
2制备方法
(1)按照选定重量份数称取人参、当归、藏红花、红花,加入10倍药物重量的质量浓度为75%乙醇提取2次,每次1.5h,合并提取液并过滤,回收乙醇并减压浓缩至60℃下相对密度1.20的浓缩液I,备用;
(2)按照选定重量份数称取血竭、桃仁、甜瓜子、土元、骨碎补、川牛膝,加入纯化提取2次,第一次加10倍药物重量的纯化水提取2h,第二次加10倍药物重量的纯化水提取1h,合并提取液并过滤,浓缩至80℃下相对密度1.15的浓缩液II,备用;
(3)按照选定重量份数称取黄瓜子、制乳香、制没药、川断、川椒、川芎、自然铜、赤芍、杏仁,加入纯化水提取2次,第一次加10倍药物重量的纯化水提取2h,第二次加10倍药物重量的纯化水提取1h,过滤、减压浓缩至60℃下相对密度1.20的浓缩液,并加入70%乙醇醇沉,取上清液回收乙醇,将所得沉淀物减压浓缩至60℃下相对密度1.15的浓缩液III,备用;
(4)合并上述浓缩液I、II和III,干燥,得浸膏粉,D-葡萄糖醛酸、氨基己糖、壳寡糖、壳聚糖、牛磺酸氨基单糖,然后按照常规工艺制成临床上可接受的剂型。
3大鼠骨密度对比实验
(1)动物
SPF级SD大鼠(购买自北京维通利华实验动物技术有限公司)60只(约28周),体重约280-300g,随机分为6组,每组10只,其中每组中分为正常对照组和用药对照组。
(2)实验过程
在同等条件下进行喂养,给药组按照体重的1.5%(1500mg/kg)进行给药。每周记录一次数据,喂养满90天后,每周测定一组大鼠的右股骨和左股骨下端两个敏感点的骨密度。
(3)骨密度测定
在麻醉下用美国HOLOGIG公司QDR-2000型双能X线吸收仪(变异系数(CV)<1.0%)扫描全身骨矿含量及骨密度,并分别取右股骨和左股骨下端两个敏感点,测量股骨中点处和远心端的骨密度(BMD)。
(4)实验数据统计
所有数据均采用均数±标准差(X±SD)表示,用SPSS统计软件进行分析,组间比较用方差分析,显著性差异用q检验。
(5)结果
左、右侧股骨骨密度指标明显高于对照组,差异具有显著性和非常显著性意义。
4卵巢摘除鼠实验
(1)动物
SPF级SD雌性鼠(购买自北京维通利华实验动物技术有限公司)60只(约16周),体重约200g,分为三组,第一组手术只切除脂肪,第二组摘除鼠的两侧卵巢,第三组摘除鼠的两侧卵巢。
(2)相同食物喂养,第三组添加组合物制剂,按照体重的1.5%(1500mg/kg)添加。
(3)喂养12周后,测定小鼠胫骨骨密度:
第一组正常对照组的小鼠胫骨骨密度变化不明显,略有降低,如图1;
第二组摘除两侧卵巢组的小鼠胫骨骨密度变化明显,明显降低,如图2;
第三组摘除两侧卵巢并用药组的小鼠胫骨骨密度变化不明显,明显改善,如图3。
5临床骨密度观察
(1)样本选择
骨质疏松诊断标准采用与本地男性的骨密度峰值相比,减少2个标准差(SD)以上为骨质疏松症。根据中国成人腰椎骨密度值,男性峰值为1.210±0.102g/cm2,在50~60岁年龄段,标准差为0.102,故以0.790g/cm2为骨质疏松诊断标准,低于此值即为骨质疏松患者。
病例选择2013年3月-2013年10月间,确诊为原发性骨质疏松症男性自愿者30例,年龄61-73岁,平均65.2岁。随机分为治疗组15例,对照组15例,两组一般情况比较无明显差异。
(2)服用方法
人口服剂量为3g组合物,早晚各服用一次,给药周期六个月。
(3)观察过程
测量两组的骨密度数值,给药组骨密度平均提高了12.06%,对照组骨密度下降了4.58%,有非常显著的提高骨密度效果。
| 组别 | 人数 | 给药前BMD(%) | 六个月后BMD(%) | BMD变化率(%) |
| 给药组 | 15 | 72.42±11.32 | 81.15±11.54 | +12.06±5.31 |
| 对照组 | 15 | 75.22±11.82 | 71.77±11.66 | -4.58±4.13 |
6样本跟踪
(1)、ID000427004
| 年龄 | 72 |
| 性别 | 女 |
| 身高 | 156cm |
| 体重 | 49kg |
| 第一次测量时间 | 2011-11-10 |
| 第一次BMD(g/cm2) | 0.4825 |
| 用药后测量时间 | 2012-1-12 |
| 用药后BMD(g/cm2) | 0.5032 |
(2)、ID02861769
(3)、ID700242064
| 出生年月日 | 1945-1-27 |
| 年龄 | 66 |
| 性别 | 女 |
| 身高 | 155cm |
| 体重 | 50kg |
| 第一次测量时间 | 2011-12-19 |
| 第一次BMD(g/cm2) | 0.431 |
| 用药后测量时间 | 2012-2-6 |
| 用药后BMD(g/cm2) | 0.530 |
(4)、ID50767298
| 出生年月日 | 1953-6-9 |
| 年龄 | 58 |
| 性别 | 女 |
| 身高 | 163cm |
| 体重 | 60kg |
| 第一次测量时间 | 2012-1-4 |
| 第一次BMD(g/cm2) | 0.806 |
| 用药后测量时间 | 2012-2-8 |
| 用药后BMD(g/cm2) | 0.817 |
(5)、ID62982
| 出生年月日 | 1955-3-15 |
| 年龄 | 56 |
| 性别 | 女 |
| 身高 | 163cm |
| 体重 | 60kg |
| 第一次测量时间 | 2011-11-10 |
| 第一次BMD(g/cm2) | 0.822 |
| 用药后测量时间 | 2011-12-12 |
| 用药后BMD(g/cm2) | 0.844 |
(6)、ID18137
| 出生年月日 | |
| 年龄 | 67 |
| 性别 | 女 |
| 身高 | 176cm |
| 体重 | 110kg |
| 第一次测量时间 | 2011-1-12 |
| 第一次BMD(g/cm2) | 1.014 |
| 用药后测量时间 | 2011-12-26 |
| 用药后BMD(g/cm2) | 1.029 |
(7)、ID398748
(8)、ID26921
| 出生年月日 | 1953-3-19 |
| 年龄 | 58 |
| 性别 | 女 |
| 身高 | 159cm |
| 体重 | 70kg |
| 第一次测量时间 | 2011-11-10 |
| 第一次BMD(g/cm2) | 0.811 |
| 用药后测量时间 | 2012-1-17 |
| 用药后BMD(g/cm2) | 0.824 |
(9)、ID20105
| 出生年月日 | 1953-3-19 |
| 年龄 | 58 |
| 性别 | 女 |
| 身高 | 159cm |
| 体重 | 71kg |
| 第一次测量时间 | 2011-11-10 |
| 第一次BMD(g/cm2) | 0.778 |
| 用药后测量时间 | 2012-2-2 |
| 用药后BMD(g/cm2) | 0.824 |
(10)、ID398748
Claims (7)
1.一种增加骨密度的组合物,其特征在于,其原料重量组成为:
D-葡萄糖醛酸5—30重量份、氨基己糖5—35重量份、壳寡糖5—50重量份、壳聚糖5—40重量份、人参5—20量份、牛磺酸氨基单糖5—50重量份、黄瓜子10—80重量份、制乳香2—50重量份、制没药2—50重量份、当归3—60重量份、藏红花2—30重量份、红花5—50重量份、血竭5—50重量份、桃仁3—50重量份、甜瓜子10—60重量份、土元5—50重量份、骨碎补5—50重量份、地骨皮10—50份、川牛膝3--50重量份、川断5—50重量份、川椒5—50重量份、川芎5—50重量份、自然铜2—20重量份、赤芍5—50重量份、杏仁3--50重量份。
2.根据权利要求1所述的组合物,其特征在于,所述组合物的原料重量组成为:D-葡萄糖醛酸20重量份、氨基己糖20重量份、壳寡糖20重量份、壳聚糖20重量份、牛磺酸氨基单糖20重量份、人参10重量份、黄瓜子50重量份、制乳香30重量份、制没药30重量份、当归30重量份、藏红花20重量份、红花30重量份、血竭30重量份、桃仁30重量份、甜瓜子30重量份、土元30重量份、骨碎补30重量份、地骨皮30重量份、川牛膝30重量份、川断30重量份、川椒30重量份、川芎30重量份、自然铜10重量份、赤芍30重量份、杏仁40重量份。
3.一种制备权利要求1或2所述组合物的方法,其特征在于,包括如下步骤:
(1)按照选定重量份数称取人参、当归、藏红花、红花,加入10倍药物重量的质量浓度为50-80%乙醇提取1-3次,每次1-3h,合并和过滤所得提取液,回收乙醇,然后将所得滤液减压浓缩至60℃下相对密度1.15-1.25的浓缩液I,备用;
(2)按照选定重量份数称取血竭、桃仁、甜瓜子、土元、骨碎补、地骨皮、川牛膝,加入10倍药物重量的纯化水提取1-3次,每次1-3小时,合并和过滤所得提取液,然后将所得滤液减压浓缩至80℃下相对密度1.10-1.20的浓缩液II,备用;
(3)按照选定重量份数称黄瓜子、制乳香、制没药、川断、川椒、川芎、自然铜、赤芍、杏仁,加入10倍药物重量的纯化水提取1-3次,每次1-3小时,合并和过滤所得提取液,将所得滤液减压浓缩至60℃下相对密度1.15-1.25的浓缩液,并加入50-80%乙醇醇沉,取上清液回收乙醇,减压浓缩至60℃下相对密度1.10-1.20的浓缩液III,备用;
(4)合并上述浓缩液I、II和III,干燥,得浸膏粉,加入D-葡萄糖醛酸、氨基己糖、壳寡糖、壳聚糖、牛磺酸氨基单糖,常规工艺制成临床上可接受的剂型。
4.根据权利要求3所述的制备方法,其特征在于,包括如下步骤:
(1)按照选定重量份数称取人参、当归、藏红花、红花,加入10倍药物重量的质量浓度为75%乙醇提取2次,每次1.5h,合并提取液并过滤,回收乙醇并减压浓缩至60℃下相对密度1.20的浓缩液I,备用;
(2)按照选定重量份数称取血竭、桃仁、甜瓜子、土元、骨碎补、地骨皮、川牛膝,加入纯化提取2次,第一次加10倍药物重量的纯化水提取2h,第二次加10倍药物重量的纯化水提取1h,合并提取液并过滤,浓缩至80℃下相对密度1.15的浓缩液II,备用;
(3)按照选定重量份数称取黄瓜子、制乳香、制没药、川断、川椒、川芎、自然铜、赤芍、杏仁,加入纯化水提取2次,第一次加10倍药物重量的纯化水提取2h,第二次加10倍药物重量的纯化水提取1h,过滤、减压浓缩至60℃下相对密度1.20的浓缩液,并加入70%乙醇醇沉,取上清液回收乙醇,将所得沉淀物减压浓缩至60℃下相对密度1.15的浓缩液III,备用;
(4)合并上述浓缩液I、II和III,干燥,得浸膏粉,D-葡萄糖醛酸、氨基己糖、壳寡糖、壳聚糖、牛磺酸氨基单糖,然后按照常规工艺制成临床上可接受的剂型。
5.权利要求1或2所述的组合物在制备具有增加骨密度作用的药物中的应用。
6.权利要求1或2所述的组合物在制备具有增加骨密度作用的保健食品中的应用。
7.权利要求1或2所述的组合物在制备具有增加骨密度作用的食品中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710233326.2A CN106974992A (zh) | 2017-04-11 | 2017-04-11 | 一种增加骨密度的组合物及其应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710233326.2A CN106974992A (zh) | 2017-04-11 | 2017-04-11 | 一种增加骨密度的组合物及其应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106974992A true CN106974992A (zh) | 2017-07-25 |
Family
ID=59345305
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710233326.2A Pending CN106974992A (zh) | 2017-04-11 | 2017-04-11 | 一种增加骨密度的组合物及其应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106974992A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112472713A (zh) * | 2020-12-03 | 2021-03-12 | 爱希(北京)国际咨询有限公司 | 一种防治骨质疏松的组合物及其应用 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1134286A (zh) * | 1995-04-28 | 1996-10-30 | 冯文光 | 壮骨宁药物及其制作方法 |
| JP2008169168A (ja) * | 2007-01-15 | 2008-07-24 | Masahiro Wada | 骨密度向上剤 |
| CN101618133A (zh) * | 2008-06-30 | 2010-01-06 | 广州白云山和记黄埔中药有限公司 | 强阳保肾药物在制备防治骨质疏松症药物中的应用 |
| CN103355660A (zh) * | 2012-04-11 | 2013-10-23 | 北京红墙生物工程有限公司 | 一种改善骨质的能增强骨密度的保健食品及其制备方法 |
| CN104127861A (zh) * | 2014-07-31 | 2014-11-05 | 漳州片仔癀药业股份有限公司 | 一种具有增加骨密度作用的药物组合物及其制备方法 |
-
2017
- 2017-04-11 CN CN201710233326.2A patent/CN106974992A/zh active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1134286A (zh) * | 1995-04-28 | 1996-10-30 | 冯文光 | 壮骨宁药物及其制作方法 |
| JP2008169168A (ja) * | 2007-01-15 | 2008-07-24 | Masahiro Wada | 骨密度向上剤 |
| CN101618133A (zh) * | 2008-06-30 | 2010-01-06 | 广州白云山和记黄埔中药有限公司 | 强阳保肾药物在制备防治骨质疏松症药物中的应用 |
| CN103355660A (zh) * | 2012-04-11 | 2013-10-23 | 北京红墙生物工程有限公司 | 一种改善骨质的能增强骨密度的保健食品及其制备方法 |
| CN104127861A (zh) * | 2014-07-31 | 2014-11-05 | 漳州片仔癀药业股份有限公司 | 一种具有增加骨密度作用的药物组合物及其制备方法 |
Non-Patent Citations (1)
| Title |
|---|
| 林飞等: "《保健食品安全性实验方法实用操作手册》", 30 September 2015, 河北科学技术出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112472713A (zh) * | 2020-12-03 | 2021-03-12 | 爱希(北京)国际咨询有限公司 | 一种防治骨质疏松的组合物及其应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102670994A (zh) | 一种具有缓解体力疲劳功能的组合物及其制备方法 | |
| CN104873624A (zh) | 一种用于痛风性关节炎的药物组合物 | |
| CN104000197B (zh) | 一种缓解疲劳的保健品或药物组合物及其制备方法和用途 | |
| US9855308B2 (en) | Composition for amelioration of peri- and post-menopausal symptoms and a process for producing the same | |
| CN104127861B (zh) | 一种具有增加骨密度作用的药物组合物及其制备方法 | |
| CN103610795B (zh) | 一种杜仲降压口服制剂的制备方法 | |
| CN104257762B (zh) | 一种药物组合物及其预防和治疗骨质疏松的用途 | |
| CN104352921B (zh) | 具有增加骨密度功效的中药组合物及其制备方法和应用 | |
| CN106974992A (zh) | 一种增加骨密度的组合物及其应用 | |
| CN102626463A (zh) | 一种增加骨密度、防治骨质疏松症的天然药物组合物 | |
| CN117599125B (zh) | 一种用于治疗骨质疏松症的补钙壮骨中药组合物及制法和应用 | |
| CN101708231A (zh) | 降压、降脂用于改善睡眠的口服液及制备方法 | |
| CN117545497A (zh) | 用于治疗骨和关节疾病的源自药材的药物组合物及用于制备其的方法 | |
| CN101375962B (zh) | 一种活血通络制剂及其制备方法 | |
| CN105169149A (zh) | 一种治疗痰火瘀结型甲状腺癌的中药组合物及制备方法、应用 | |
| CN105381154A (zh) | 一种含辣木的药物组合物及其制剂的制备方法 | |
| CN100493556C (zh) | 一种治疗抑郁情绪障碍性疾病的药物 | |
| CN105853766A (zh) | 一种中药制剂在制备治疗原发性高血压药物中的用途 | |
| CN118453749B (zh) | 一种治疗交感神经型颈椎病的药物组合物及其制备方法和用途 | |
| CN103798475B (zh) | 改善围绝经期亚健康状态的中草药蜜茶(无糖颗粒)及制备工艺 | |
| CN104161936B (zh) | 一种预防和治疗绝经后骨质疏松的中药组合物及其制备方法 | |
| CN110038084B (zh) | 一种治疗绝经后干眼的药物组合物及其制备方法和用途 | |
| CN107822141A (zh) | 一种具有祛黄褐斑功效的组合物、应用及其保健食品 | |
| CN104547742A (zh) | 一种治疗高血压的中药制剂及其制备方法 | |
| CN118383509A (zh) | 具有降压功能的保健品组合物及制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170725 |
|
| WD01 | Invention patent application deemed withdrawn after publication |